AmethIntel

Decision intelligence for pharma, biotech, healthtech & investors. Clinical trials, patents, science & market evidence.
Every finding cited, data handed over.

[AmethIntel @AmethIntel]

Every deal rests on assumptions. Ground yours in data.

AmethIntel brings together clinical trials, patents, publications, and market evidence—then turns them into decision-ready intelligence within 48 hours.

Every finding is sourced.

Better data. Better decisions.

[AmethIntel @AmethIntel]

An application of AmethIntel is to support academic research scientists with the data and the language the industry and investors want for partnership.

[AmethIntel @AmethIntel]

@adamfeuerstein @DrPatrick Is the novelty the cross-population extrapolation to address the use of CIS evidence to support approval in high-grade papillary-only NMIBC in its disease-specific guidance?

[Adam Feuerstein ✡️ @adamfeuerstein]

Yesterday, the FDA approved the $IBRX drug Anktiva to treat the more common "papillary" type of non-muscle invasive bladder cancer.

The approval was based on a single arm study, reversing the agency's prior regulatory standard.

A victory for ImmunityBio and @DrPatrick ? Maybe half.

The new FDA standard for papillary NMIBC will now be broadly applied. Did anyone listen to the $JNJ earnings call on Tuesday? Here's R&D chief John Reed, speaking about its bladder cancer drug, Inlexzo:

"The FDA has invited us to submit for an expansion of our label into that population."

Inlexzo sales in Q3 were "north of $90 million," J&J said.

[AmethIntel @AmethIntel]

A therapy can show clinical benefit and still face a hard commercial path.
Does your development plan generate the evidence payers will require?
How does the treatment fit into existing care pathways?
What could justify adoption and reimbursement?

https://t.co/bYsvsgFRnh

[AmethIntel @AmethIntel]

Everyone who needs your product won't pay for it.

In healthcare it becomes more important. A potential customer turns into paying customer after the regulator, prescriber, payer, TPA have all okayed it.

#StartupStrategy #ProductMarketFit #BusinessStrategy #Founders

[AmethIntel @AmethIntel]

The market is not the patient count.
Eligibility criteria, diagnosis rates, prescriber behaviour, and competitors all determine the market.
A credible investment case links the invention to its addressable market.

We make it explicit and transparent.

https://t.co/bYsvsgFjxJ

[AmethIntel @AmethIntel]

@OncData @HundalJasmin This brings in an interesting scenario - could GLP-1–based therapy reduce future cancer incidence—or merely shift risk through weight loss and helping metabolic disease?

[AmethIntel @AmethIntel]

IP, differentiation, pathway (regulatory, prescriber, payer) and valuation models.

We help companies to know where they stand. Take a diagnostic test. https://t.co/ny021sW7a2.

[AmethIntel @AmethIntel]

IP only creates value when it is tied to clinical development, competitor positioning, and the differentiation thesis.
We connect those pieces on one board.

See the approach: https://t.co/bYsvsgFRnh

[AmethIntel @AmethIntel]

In our recent study on CEACAM5, about 85% of affected patients were not included in the clinical trials.
(https://t.co/wjuJtjAz2S)

[AmethIntel @AmethIntel]

A novel molecule is not clinical differentiation.
Which patients can actually benefit?
What have competing approaches already shown?
Where do their limitations create an opening?

Where are you leaving white space on the table?
We map it in 48 hours. https://t.co/bYsvsgFRnh

[AmethIntel @AmethIntel]

A novel molecule is not clinical differentiation.
Which patients can actually benefit?
What have competing approaches already shown?
Where do their limitations create an opening?

Where are you leaving white space on the table?
We map it in 48 hours. https://t.co/bYsvsgFRnh

[AmethIntel @AmethIntel]

A patent estate is not an IP strategy.
You need the claims, the surrounding landscape, the real barriers to competitors, and the vulnerabilities that could affect your own development or partnering options.

[AmethIntel @AmethIntel]

You have patents. Do you have a defensible business?
Not automatically.
What do the claims actually protect? How do they sit against competing estates? Where are the boundaries? What room remains to operate or partner?

[AmethIntel @AmethIntel]

In a recent CEACAM5 analysis, we screened 1,000+ patents.

The picture that emerged was not “strong patent thicket = barrier.” It was more nuanced: permeable in places, tightly held in others, and revealing clear paths for focused entrants.

[AmethIntel @AmethIntel]

What if the analyses you need for the business plan—IP & patents, clinical trials & competitors, prescribers/payers/regulation, opportunities & gaps, strategy & valuation assumptions—were available on one dashboard within 48 hours?

Open the example: https://t.co/bYsvsgFjxJ

[AmethIntel @AmethIntel]

You have the science.
Investors still need the investment case.

Defensible IP. Clinical differentiation. Credible regulatory path. Reachable market. Capital plan tied to value inflection points.
That is where science becomes a fundable business.
→ https://t.co/bYsvsgFRnh

[AmethIntel @AmethIntel]

The number that matters is the number that survives all four filters:
Science → diagnosis → treatment → market
That's why we don't stop at market size.
We test the path to the market.
3/3

[AmethIntel @AmethIntel]

The same principle applies to biotech.
A target population is not automatically a treatable population.
A treated population is not automatically a reimbursed population.
And a reimbursed population is not automatically a commercially reachable population.
2/3

[AmethIntel @AmethIntel]

A second lesson from industrial diligence:
Installed capacity is not the same thing as usable capacity.
A plant can have the equipment, licences, and theoretical output—and still be unable to deliver the business plan's numbers.
The gap is often hidden in details.
1/3